Syndax Pharmaceuticals SNDX Royalty Interest Financing Less Current Portion
Royalty Interest Financing Less Current Portion at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept sndx:RoyaltyInterestFinancingLessCurrentPortion.
The official record: Syndax Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's royalty interest financing less current portion.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's royalty interest financing less current portion?
- Syndax Pharmaceuticals (SNDX) reported royalty interest financing less current portion of $343.91M in Q4 2025.
- What does royalty interest financing less current portion mean?
- This represents long-term financial obligations related to the monetization of future royalty streams, excluding amounts due within one year. It indicates the extent to which the company has leveraged its future intellectual property revenue to secure upfront capital. This metric is crucial for evaluating the long-term impact of non-dilutive financing strategies on future cash flows.